Blueprint Medicines Corporation Revised revenue guidance for the full year 2024. For the year, company now anticipates approximately $390 million to $410 million in global AYVAKIT net product revenues for all approved indications in 2024, an increase from the previous range of $360 million to $390 million. This updated guidance reflects continued execution in the global launch for ISM, as well as a stronger than anticipated first quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105.6 USD | -0.75% | +2.67% | +14.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.44% | 6.61B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024